Lifecore Biomedical, Inc. \de\.
- LFCR · Nasdaq
- Pharmaceutical Preparations
- Chaska, MN
- 406 employees
- CIK 0001005286
Updated from SEC filings through
Top things to know
Executives
-
Paul Josephs President and chief executive officer of Lifecore 8-K, 2026-11-04 - Thomas D. Salus Chief Legal & Administration 4, 2026-04-16
-
Ryan D. Lake Chief Financial Officer DEF 14A, 2026-04-24
What leadership is saying
“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginni”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Lifecore Biomedical, Inc. \de\ is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Chaska, MN. It trades as LFCR on Nasdaq. Revenue was $129M in the fiscal year ending May 25, 2025, +0.5% from the year before. It reported about 406 employees. Paul Josephs is President and chief executive officer of Lifecore.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $129M 10-KT, 2026-03-16 | $128M 10-KT, 2026-03-16 | $103M 10-K, 2024-08-26 | $111M 10-K, 2024-08-26 | $101M 10-K, 2024-03-20 |
| Operating income | -$17.2M 10-KT, 2026-03-16 | -$8.8M 10-KT, 2026-03-16 | -$21.8M 10-K, 2024-08-26 | -$11.8M 10-K, 2024-08-26 | -$8.8M 10-K, 2024-03-20 |
| SG&A | $44.0M 10-KT, 2026-03-16 | $40.5M 10-KT, 2026-03-16 | $39.0M 10-K, 2024-08-26 | $34.7M 10-K, 2024-08-26 | $27.7M 10-K, 2024-03-20 |
| Net income | -$38.7M 10-KT, 2026-03-16 | $12.0M 10-KT, 2026-03-16 | -$99.6M 10-K, 2024-08-26 | -$117M 10-K, 2024-08-26 | -$32.3M 10-K, 2024-03-20 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Paul Josephs President & Chief Executive Officer at Lifecore Biomedical | President and chief executive officer of Lifecore | 8-K, 2026-11-04 |
| Ryan D. Lake | Named in proxy bio: Chief Financial Officer | DEF 14A, 2026-04-24 |
| Thomas D. Salus | Chief Legal & Administration | 4, 2026-04-16 |
| Christopher S. Kiper | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| Humberto C. Antunes | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| Jason Aryeh | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| Katrina L. Houde | Board member (per proxy) bio: Director, Chair of the Board | DEF 14A, 2026-04-24 |
| Matthew E. Korenberg | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| Nelson Obus | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| Paul H. Johnson | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| Joshua E. Schechter | Board member (per proxy) bio: Director | DEF 14A, 2025-09-18 |
What Lifecore Biomedical, Inc. \de\ does
Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore”, the “Company”, “we” or “us”), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities.S.
Shares and governance
| Shares outstanding | 37.9 million (as of October 28, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $223M (as of June 30, 2025) | 10-KT, March 16, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting April 24, 2026 (filed April 24, 2026) | DEF 14A, April 24, 2026 |
| Auditor | Bdo Usa, P.c. (Minneapolis, Minnesota) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 8.01 Other events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-20
- Item 8.01 Other events
- 8-K filed 2026-09-29
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-09-28
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-02
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-05
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-16
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Lifecore Biomedical, Inc. \de\
- What does Lifecore Biomedical, Inc. \de\ do?
- In its own words, from Item 1 of its 10-K: "Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore”, the “Company”, “we” or “us”), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities.S."
- What is Lifecore Biomedical, Inc. \de\'s revenue?
- $129M for the fiscal year ending May 25, 2025, from its 10-KT filed March 16, 2026.
- Is Lifecore Biomedical, Inc. \de\ profitable?
- Lifecore Biomedical, Inc. \de\ reported net income of -$38.7M for the fiscal year ending May 25, 2025.
- How many employees does Lifecore Biomedical, Inc. \de\ have?
- About 406 as of May 25, 2025, as stated in its annual report.
- Who is the CEO of Lifecore Biomedical, Inc. \de\?
- Paul Josephs, President and chief executive officer of Lifecore, as named in a 8-K filed November 4, 2026.
- Where is Lifecore Biomedical, Inc. \de\ headquartered?
- Chaska, MN.
- What is Lifecore Biomedical, Inc. \de\'s stock ticker?
- LFCR on Nasdaq.
- What industry is Lifecore Biomedical, Inc. \de\ in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Lifecore Biomedical, Inc. \de\'s website?
- lifecore.com.
- When does Lifecore Biomedical, Inc. \de\ report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is Lifecore Biomedical, Inc. \de\ a public company?
- Yes. Lifecore Biomedical, Inc. \de\ files with the SEC under CIK 0001005286 and trades as LFCR.
- Who audits Lifecore Biomedical, Inc. \de\?
- Bdo Usa, P.c., Minneapolis, Minnesota, as named in its latest annual report (10-K).
- How many shares of Lifecore Biomedical, Inc. \de\ are outstanding?
- 37.9 million shares as of October 28, 2026, from its 10-Q filed November 4, 2026.
- What is Lifecore Biomedical, Inc. \de\'s public float?
- $223M as of June 30, 2025, as reported on the cover of its 10-KT filed March 16, 2026.
- How many business segments does Lifecore Biomedical, Inc. \de\ report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Lifecore Biomedical, Inc. \de\'s annual shareholder meeting?
- April 24, 2026, per its proxy statement (DEF 14A) filed April 24, 2026.